摘要 三诺生物 2025 年上半年 CGM 业务销售额超 2 亿元，海外收入占比 25%-30%，整体毛利率超 45%，海外及临床销售毛利率更高。海外市 场医保进展顺利，现金市场也在积极部署，全年目标销售额为 4-6 亿元， 并已实现盈利，销售利润率超 20%。 公司撤回 CGM 一代产品在美国的注册申请，集中资源推进二代产品， 旨在优化性能、提高良性转化，增强用户粘性，提升技术水平和优化生 产工艺，以确保二代产品在美国市场的长期竞争力。 国内 CGM 市场线上销售占比高，临床渠道收入同比增长超 40%，已进 入 600 多家等级医院。销售费用率下降主要由于二代产能优化及线上内 容电商投入减少，未来费用投入预计趋于平缓。 三诺生物一代 CGM 产品良率已接近 99%，预计 2025 年可实现，二代 产品良率提升需更长时间。公司基于二代产能和良率提升调整市场推广 节奏。 Trividia 2025 年收入增长超出年初预期，但利润受财务费用和汇兑损 益影响同比下降。毛利率下降是由于 PBM 和 Medicare 市场投放更多仪 器，预计下半年增长将超年初预期。 三诺生物 20250828 Q&A 三诺生物 202 ...

Core Viewpoint - The company reported a decline in overall revenue and net profit for 2024, while specific segments like blood glucose management and emergency solutions showed significant growth [1][2]. Financial Performance - In 2024, the company achieved revenue of 7.566 billion yuan, a year-over-year decrease of 5.09%, and a net profit attributable to shareholders of 1.806 billion yuan, down 24.63% year-over-year [1]. - For Q1 2025, the company reported revenue of 2.436 billion yuan, an increase of 9.17% year-over-year, with a net profit of 625 million yuan, down 5.26% year-over-year [1]. Segment Performance - The blood glucose management and POCT solutions segment generated revenue of 1.03 billion yuan in 2024, growing by 40.20% year-over-year, driven by a significant increase in CGM and expansion of BGM customer base [2]. - The emergency solutions segment achieved revenue of 239 million yuan, up 34.05% year-over-year, benefiting from the certification and technological upgrades of the AED products [2]. - The respiratory therapy solutions segment saw revenue decline to 2.597 billion yuan, down 22.42% year-over-year, primarily due to fluctuations in public demand [2]. - The home health monitoring solutions segment reported revenue of 1.564 billion yuan, a slight decrease of 0.41% year-over-year, with some products experiencing growth despite high base effects [2]. - Clinical instruments and rehabilitation solutions generated revenue of 2.093 billion yuan, a marginal increase of 0.24% year-over-year, with certain product categories showing positive trends [2]. Profitability and Cost Management - The company achieved a gross margin of 50.14% in 2024, a decrease of 1.22 percentage points year-over-year, but is expected to stabilize and improve in Q1 2025 to 50.30% [3]. - The sales, management, and financial expense ratios for 2024 were 17.99%, 5.66%, and -3.12%, respectively, with a focus on optimizing costs and resource utilization [3]. International Expansion - The company’s overseas market revenue reached 949 million yuan in 2024, reflecting a year-over-year growth of 30.42%, supported by product registrations and localized team development [3]. Investment Outlook - The company is focused on the home medical device sector, particularly in respiratory and oxygen therapy, blood glucose management, and infection control, with rapid growth in international markets expected to enhance growth potential [4]. - Revenue projections for 2025-2027 are estimated at 8.548 billion yuan, 9.710 billion yuan, and 11.096 billion yuan, with corresponding year-over-year growth rates of 13.0%, 13.6%, and 14.3% [4].